Resverlogix - Light at the End of the Tunnel - Targeted 250 MACE Events Reached

"In determining the valuation of the Company, we looked at various scenario’s with subsequent valuations. In each of these scenarios we assumed a reduction in MACE of at least 25% with secondary endpoints of potential improved renal risk marker eGFR and cognitive marker MoCA score improvement of at least 10-20% and 1.0-2.0 points respectively relative to placebo group. We feel that a potential reduction of MACE of greater than 35% and even 40% is possible and therefore have provided sensitivity and enhanced value modelling for these efficacy endpoints if reached. We have increased our valuation with the publication of topline data to be expected within 2-3 months. We believe that Resverlogix remains gravely undervalued at the current share price of CAD 4.05. We feel that the company’s potential for MACE reduction of greater than 30% is possible and as a result suggest that the current total value should be of CAD 3.5-4.6 billion, or CAD 17.50-23.07 per share. This represents a substantial upside from the current share price."